Yoga Intervention for Cancer Survivors
|ClinicalTrials.gov Identifier: NCT01228955|
Recruitment Status : Completed
First Posted : October 27, 2010
Last Update Posted : April 6, 2017
Impaired health related quality of life (HRQOL) including fatigue, problems with sleep and psychosocial well being (physical, emotional, and spiritual) have been noted in adult cancer survivors. Physical domain is one of the most common measured indicators of HRQOL. Despite the tremendous implications of having an impaired QOL, few studies have staged interventions aimed at improving HRQOL in a heterogeneous group of cancer survivors. There is little literature examining whether a yoga intervention is feasible in a heterogeneous group of cancer survivors.
The proposed research will utilize Vanderbilt Ingram Cancer Center (VICC), Nashville General Hospital (NGH) and REACH for Survivorship program for a pilot study. The investigators will see if a study using a broad range of diagnoses is feasible for a Yoga Intervention.
|Condition or disease|
|Cancer Survivors Yoga|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||48 participants|
|Official Title:||Yoga Intervention for Cancer Survivors|
|Study Start Date :||February 2010|
|Actual Primary Completion Date :||March 2012|
|Actual Study Completion Date :||March 2012|
Group will enter a 10 week yoga class
- Number of Cancer Survivors interested and willing to participate in a 10 week yoga class at Vanderbilt Ingram Cancer Center (VICC) and at Nashville General Hospital [ Time Frame: 12 months ]The investigators will be opening up an hourly yoga class for 10 weeks to all cancer survivors at VICC and at Nashville General Hospital
- Levels of Fatigue using the SF-36 and Psychological Distress using BSI-18 [ Time Frame: 12 months ]Participants in the Yoga Study will be asked to complete the SF-36 and BSI-18 at three different time points in the study. Prior to start of a yoga class, at the end of the 10 week yoga class and 3 months after the completion of the yoga class.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01228955
|United States, Tennessee|
|Vanderbilt University Medical Center|
|Nashville, Tennessee, United States, 37232|
|Principal Investigator:||Debra L Friedman, MD, MS||Vanderbilt University Medical Center|